Analysis of clinical characteristics and outcomes of ALK positive (ALK+) patients treated with ALK inhibitors (ALKi).

e20550Background: Non-small cell lung cancer (NSCLC) harboring anaplastic lymphoid kinase (ALK) rearrangements represents a selective population who responds to targeted therapies. This study explo...